<DOC>
	<DOC>NCT00162201</DOC>
	<brief_summary>Study to assess changes in synovial tissue before and after treatment with Abatacept in subjects with RA who remained on their background disease modifying anti-arthritis medications but who have failed previous therapy with anti-TNF (tumor necrosing factor)blocking agents.</brief_summary>
	<brief_title>An Exploratory Study of Changes in Synovial Immune Responses Following BMS-188667 Therapy in Subjects With Active Rheumatoid Arthritis on Background DMARDs Who Have Failed Anti-TNF Therapy</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Abatacept</mesh_term>
	<criteria>RA for at least 1 year Clear clinical signs of active RA in 1 knee joint Meet ARA (1987) criteria for diagnosis of RA and ACR (1991) criteria for RA functional classes I, II, or III Inadequate clinical response to a minimum of 3 months of therapy with antiTNFblocking agents Taking background DMARDs for a minimum of 3 months and at stable doses for at least 28 days Serious bacterial infection in last 3 months History of TB History of cancer within 5 years Evidence of latent or active bacterial or viral infection Intraarticular corticosteroids within 3 months Exposure to live vaccines Exposure to CTLA4Ig or BMS188667 Treatment with immunoadsorption column(s), mycophenolate mofetil, leflunomide, anakinra, cyclosporine, etanercept, adalimumab, infliximab, azathioprine, oral or parenteral gold, Dpenacillamine, calcineurin inhibitors, cyclophosphamide or other alkylating agents</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2011</verification_date>
</DOC>